Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

Licensed meningococcal conjugate vaccines and the investigational meningococcal B vaccines, once they are licensed, have the potential to reduce the incidence of invasive meningococcal disease to ...

Both Novartis and Pfizer have serogroup B vaccines in development. Globally, infants are at the highest risk of infection with meningococcal disease, and so vaccines that can be administered to ...

Serogroup B vaccines should also be available to provide further protection against this important cause of meningococcal disease. With vaccines to protect against the five serogroups that are ...

Since 1 er January 2025, a new vaccination requirement for infants has entered into force against ACWY meningococci and against meningococcus B. Meningococcal C vaccination, already mandatory ...

Hundreds have already taken advantage of the CLP’s free meningococcal B vaccination program, which provides protection for infants aged six weeks to two years, and teens aged 14 to 19 years.